-
MedImmune to create standalone biologics company Viela Bio: 5 things to know
MedImmune will create a standalone company for early-stage inflammatory and autoimmunity biologics. -
Biologics, opioids will be magic words at AAOS 2018 meeting: 5 insights
Surgeons attending the American Academy of Orthopaedic Surgeons 2018 Annual Meeting in New Orleans March 6 to 10 can expect to discuss biologics and opioids, according to Medscape. -
First primate study: stem cells mature into nerve cells in rhesus monkeys with SCI, improve grip — 6 insights
Researchers grafted human spinal cord-derived neural progenitor cells into cervical spinal cord injury sites in rhesus monkeys in a study in Nature Medicine. The human stem cells matured into nerve cells in the monkeys, spurring neuronal connections and improving the monkeys' grip. -
New 3-D printed device enables access to single-cell sequencing, used in HSS study of RA patients: 5 things to know
Researchers at the New York Genome Center and New York University in New York City developed a 3-D printed, portable and low-cost microfluidic device to facilitate access to single-cell sequencing. The researchers used the device to study synovial tissue from patients with rheumatoid arthritis at the New York City-based Hospital for Special Surgery and published their findings in Nature Communications. -
Bioventus, LifeLink to co-develop next generation spine and trauma bone allograft
Bioventus will co-develop a next generation bone allograft solution for spine and trauma surgery with Tampa, Fla.-based LifeLink Tissue Bank. -
Johnson & Johnson, Trinity College Dublin collaborate on new global 3D bioprinting laboratory — 6 insights
Johnson & Johnson is collaborating with Advanced Materials and BioEngineering Research to establish a 3-D bioprinting laboratory. Work on the new laboratory will begin in the first quarter of 2018. -
First patient dosed with non-opioid therapy for OA pain in Centrexion Therapeutics' Phase 3 clinical trial: 4 insights
The first patient in Centrexion Therapeutics Corp.'s Phase 3 VICTORY-1 clinical trial has been dosed with CNTX-4975, a synthetic trans-capsaicin injection for the treatment of chronic moderate to severe pain due to knee osteoarthritis.
Page 37 of 37